Metformin vs Rapamycin (Sirolimus)

Mechanism

Metformin activates AMP-activated protein kinase (AMPK) via inhibition of mitochondrial Complex I, increasing the AMP/ATP ratio. AMPK activation triggers a cascade of metabolic effects: inhibition of hepatic gluconeogenesis, enhanced glucose uptake in skeletal muscle via GLUT4 translocation, and suppression of mTORC1 signaling. In the longevity context, metformin's mTOR inhibition mimics caloric restriction signaling, activating autophagy, reducing inflammatory cytokines (IL-6, TNF-a), decreasing insulin and IGF-1 signaling, and modulating the gut microbiome (increasing Akkermansia muciniphila). It also reduces AGE formation and mitochondrial ROS production.

Standard Dosing

Research indicates 500-1000 mg daily for longevity/anti-aging protocols. Standard diabetes dosing: 500-2550 mg daily.

Timing

Take with food (dinner) to minimize GI side effects. Extended-release formulation once daily with dinner. Immediate-release split into 2-3 doses with meals.

Cycle Duration

Ongoing for longevity applications. The TAME (Targeting Aging with Metformin) trial is designed to assess long-term geroprotective effects.

Side Effects

• GI distress: nausea, diarrhea, bloating, metallic taste (common initially, improves with XR formulation)
• Vitamin B12 deficiency (with chronic use — monitor annually)
• Lactic acidosis (rare but serious — primarily in renal impairment)
• Potential blunting of exercise-induced mitochondrial adaptations (debated)
• Weight loss (often considered a benefit)

Contraindications

• eGFR <30 mL/min/1.73m2 (contraindicated) or <45 (use with caution)
• Acute or chronic metabolic acidosis including lactic acidosis
• Heavy alcohol consumption
• Acute decompensated heart failure
• Hepatic failure
• Planned procedures with iodinated contrast dye

Best Stacking Partners

Mechanism

Rapamycin binds the intracellular protein FKBP12, and the rapamycin-FKBP12 complex inhibits mechanistic target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that integrates nutrient sensing, growth factor signaling, and cellular energy status. mTORC1 inhibition suppresses S6K1-mediated ribosomal protein synthesis, activates ULK1-mediated autophagy and mitophagy, enhances lysosomal biogenesis via TFEB nuclear translocation, reduces senescent cell accumulation, and suppresses the SASP (senescence-associated secretory phenotype). At higher chronic doses, rapamycin also inhibits mTORC2, which regulates Akt-mediated insulin signaling — this is believed to drive the metabolic side effects.

Standard Dosing

Research indicates 5-6 mg once weekly (intermittent/pulsed dosing) for longevity protocols. This weekly pulsed approach preferentially inhibits mTORC1 while allowing mTORC2 to remain functional.

Timing

Once weekly, consistent day each week. Take with or without food (food increases bioavailability by ~35% — be consistent either way). Grapefruit juice significantly increases rapamycin bioavailability via CYP3A4 inhibition — some practitioners use this intentionally to reduce pill burden.

Cycle Duration

Long-term (years) for longevity applications. The PEARL trial assessed up to 12 months of treatment in healthy older adults.

Side Effects

• Mouth ulcers/canker sores (most common, dose-dependent)
• Elevated lipids (triglycerides and LDL — typically manageable with weekly dosing)
• Impaired wound healing
• Mild immunosuppression (increased susceptibility to infections)
• Insulin resistance (primarily from mTORC2 inhibition at higher/daily doses)
• Acne-like skin eruptions
• Thrombocytopenia and leukopenia (rare at longevity doses)

Contraindications

• Active infections (immunosuppression risk)
• Poorly healing wounds or planned surgery (delays wound healing)
• Severe hepatic impairment
• Uncontrolled hyperlipidemia
• Pregnancy and breastfeeding
• Organ transplant patients on calcineurin inhibitors (specialized dosing required)
• Active infection
• Immunocompromised states
• Poorly controlled diabetes
• Wound healing (pause 2 weeks pre-surgery)

Best Stacking Partners